Reuters: Regulatory News: J&J drug wins wider approval, to treat, prevent, leg, lung clots

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

J&J drug wins wider approval, to treat, prevent, leg, lung clots Nov 2nd 2012, 20:49 Fri Nov 2, 2012 4:49pm EDT Nov 2 (Reuters) - U.S. regulators on Friday said they had approved expanded use of Johnson & Johnson's Xarelto blood thinner, to treat blood clots in the legs and lungs and to reduce the risk of such clots recurring after initial treatment. The pill is already approved to reduce the risk of such leg clots, called deep vein thrombosis, and lung clots, following knee or hip replacement surgery. It is also already approved to prevent strokes in patients with an irregular heartbeat called atrial fibrillation. "Xarelto is the first oral anti-clotting drug approved to treat and reduce the recurrence of blood clots since the approval of warfarin 60 years ago," the FDA said in a release.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions